ALK and non-small cell lung carcinoma: In the phase III PROFILE 1014 trial, crizotinib, the first-in-class ALK tyrosine kinase inhibitor, demonstrated improved outcomes compared to platinum-based chemotherapy as the first-line therapy for advanced NSCLC patients with ALK gene rearrangement.